Literature DB >> 10395316

HIV-1 entry inhibitors: evading the issue.

N L Michael, J P Moore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10395316     DOI： 10.1038/10462

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  25 in total

1.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 4.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

5.  CCL3 genotype and current depression increase risk of HIV-associated dementia.

Authors:  Andrew J Levine; Elyse J Singer; Janet S Sinsheimer; Charles H Hinkin; Jeanette Papp; Sugandha Dandekar; Allison Giovanelli; Paul Shapshak
Journal:  Neurobehav HIV Med       Date:  2009-11

6.  Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.

Authors:  P Steinberger; J Andris-Widhopf; B Bühler; B E Torbett; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

7.  The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication.

Authors:  Jocelyn Roy; Jean-Sébastien Paquette; Jean-François Fortin; Michel J Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 9.  HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis.

Authors:  Marcus Kaul
Journal:  Front Biosci       Date:  2008-01-01

10.  CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120.

Authors:  Ricky Maung; Melanie M Hoefer; Ana B Sanchez; Natalia E Sejbuk; Kathryn E Medders; Maya K Desai; Irene C Catalan; Cari C Dowling; Cyrus M de Rozieres; Gwenn A Garden; Rossella Russo; Amanda J Roberts; Roy Williams; Marcus Kaul
Journal:  J Immunol       Date:  2014-07-16       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.